RxDoctor Payments Data

Cici Liu, MD

Gynecologic Oncology · Rochester, NYNPI 1952620577

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (39.5%), education and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Intuitive Surgical at 53.2% of the total. 2025 is the largest year on record at $4,551, more than ten times the $102 reported in 2019.

$7,332in general payments, 2019–2025

Across 75 payments — averaging $97.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Medical Device Business Services, Inc.$1K
  • AstraZeneca$442
  • Myriad Genetic Laboratories, Inc.$206
  • Conmed Corporation$168
  • Johnson & Johnson$166
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$1,93926%
  • Food & beverage$2,89339%
  • Education$2,50034%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,332 in reported general payments places this provider in the 80th percentile of 154 gynecologic oncology providers in New York.

See all gynecologic oncology providers in New York

Medicare billing

Part B allowed, 2024
$175,676
Medicare patients
125
Services billed
815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol37$2,127
Clobetasol Propionate12$565
Celecoxib32$543
Nystatin14$248
Imiquimod13$174
Oxycodone Hcl27$154

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →